Top 5 Heal Care Stocks To Own For 2014

Traders simply couldn't wait for the weekend, and abandoned all hope of a repeat of yesterday's huge gains early in the day. Unlike yesterday, the economic data certainly didn't work in the favor of the broad-based S&P 500 (SNPINDEX: ^GSPC  ) , sending it modestly lower on the day.

We knew heading into today's preliminary University of Michigan consumer sentiment figure that it'd be downright difficult for optimism to surpass the nearly six-year high put up last month. The initial figure of 82.7, while still higher than many of the preceding months other than May, is nonetheless a decline, and a signal that optimism about the health of the economy may be waning.

May's industrial production also came in with a disappointing figure of flat growth compared to expectations for 0.1% growth. I'm sure investors are happy to see flat growth compared to the decline of 0.4% reported in April, but it nonetheless points to the fragility of the recovery in industrial production in the U.S.

5 Best Restaurant Stocks To Own Right Now: Genomic Health Inc (GHDX)

Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Oncotype DX Platform

The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.

Oncotype DX Breast Cancer Test

To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.

In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.

Oncotype DX Colon Cancer Test

The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.

The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.

Advisors' Opinion:

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

Top 5 Heal Care Stocks To Own For 2014: Regency Energy Partners LP (RGP)

Regency Energy Partners LP (the Partnership), incorporated on September 8, 2005, is engaged in the gathering and processing, contract compression, treating and transportation of natural gas and the transportation, fractionation and storage of natural gas liquids (NGLs). The Partnership operates in five business segments: Gathering and Processing, Joint Ventures, Contract Compression, Contract Treating, and Corporate and Others. Its assets are primarily located in Texas, Louisiana, Arkansas, Pennsylvania, California, Mississippi, Alabama, West Virginia and the mid-continent region of the United States, which includes Kansas, Colorado and Oklahoma. In May 2013, Regency Energy Partners LP closed the acquisition of Southern Union Gathering Company, LLC from Southern Union Company. In February 2014, Regency Energy Partners LP closed its acquisition of the midstream business of Hoover Energy Partners LP.

During the year ended December 31, 2012, Lone Star NGL LLC (Lone Star), a newly formed joint venture that is owned 70% by Energy Transfer Partners, L.P. (ETP) and 30% by the Partnership, acquired all of the membership interest in LDH Energy Asset Holdings LLC (LDH), a wholly owned subsidiary of Louis Dreyfus Highbridge Energy LLC. The Partnership focuses on providing midstream services in some of the most prolific natural gas producing regions in the United States, including the Eagle Ford, Haynesville, Barnett, Fayetteville, Marcellus, Bone Spring, and Avalon shales as well as the Permian Delaware basin and the mid-continent region. The Partnership provides wellhead-to-market services to producers of natural gas, which include transporting raw natural gas from the wellhead through gathering systems, processing raw natural gas to separate NGLs and selling or delivering the pipeline natural gas and NGLs to various markets and pipeline systems.

The Partnership owns and operates a fleet of compressors used to provide turn-key natural gas compression services for customer specific syst! ems. The Partnership owns and operates a fleet of equipment used to provide treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration and BTU management, to natural gas producers and midstream pipeline companies.

Gathering and Processing Operations

The Partnership operates gathering and processing assets in four geographic regions of the United States: north Louisiana, the mid-continent region of the United States, south Texas and west Texas. The Partnership�� north Louisiana assets gather, compress, treat and dehydrate natural gas in five Parishes (Claiborne, Union, DeSoto, Lincoln and Ouachita) of north Louisiana and Shelby County, Texas. Its assets also include two cryogenic natural gas processing facilities, a refrigeration plant located in Bossier Parish, a conditioning plant located in Webster Parish, an amine treating plant in DeSoto Parish, and an amine treating plant in Lincoln Parish. The Partnership�� south Texas assets gather, compress, treat and dehydrate natural gas in LaSalle, Webb, Karnes, Atascosa, McMullen, Frio and Dimmitt counties. The pipeline systems that gather this gas are connected to third-party processing plants and its treating facilities that include an acid gas reinjection well located in McMullen County, Texas.

One of the Partnership�� treating plants consists of inlet gas compression, a 60 one million cubic feet per day amine treating unit, a 55 one million cubic feet per day amine treating unit and a 40 ton (per day) liquid sulfur recovery unit. In January 2012, it completed an expansion of the treating plant, adding an incremental 20 one million cubic feet per day of treating capacity to the facility. The Partnership owns a 60% interest in ELG that includes a treating plant in Atascosa County with a 500 gallons per minute amine treater, pipeline interconnect facilities and approximately 13 miles of ten inch diameter pipeline. Talisman Energy USA Inc. and Statoil Texas Onshore Pro! perties L! P own the remaining 40% interest. It operates this plant and the pipeline for the joint venture while its joint venture partner operates a lean gas gathering system in the Edwards Lime natural gas trend that delivers to this system.

The Partnership�� west Texas gathering system assets offer wellhead-to-market services to producers in Ward, Winkler, Reeves, and Pecos counties, which surround the Waha Hub. The NGL market outlets include Lone Star's west Texas NGL pipeline. It offers producers four different levels of natural gas compression on the Waha gathering system. The Waha processing plant is a cryogenic natural gas processing plant that processes raw natural gas gathered in the Waha gathering system. The Waha processing plant also includes an amine treating facility, which removes carbon dioxide and hydrogen sulfide from raw natural gas gathered before moving the natural gas to the processing plant.

The Partnership�� mid-continent region includes natural gas gathering systems located primarily in Kansas and Oklahoma. Its mid-continent gathering assets are extensive systems that gather, compress and dehydrate low-pressure gas from approximately 1,500 wells. These systems are geographically concentrated, with each central facility located within 90 miles of the others. The Partnership also owns the Hugoton gathering system that has approximately 1,875 miles of pipeline extending over nine counties in Kansas and Oklahoma. This system is operated by a third party. Its mid-continent systems are located in two natural gas producing regions in the United States, the Hugoton Basin in southwest Kansas and the Anadarko Basin in western Oklahoma.

Joint Ventures Operations

The Partnership owns investments in four joint ventures: a 49.99% general partner interest in RIGS Haynesville Partnership Co., a general partnership, and its wholly-owned subsidiary, Regency Intrastate Gas LP (HPC); a 50% membership interest in MEP; a 30% membership interest in Lone St! ar, and a! 33.33% membership interest in Ranch JV. HPC owns RIGS, a 450-mile intrastate pipeline that delivers natural gas from northwest Louisiana to downstream pipelines and markets. MEP owns an interstate natural gas pipeline with approximately 500 miles stretching from southeast Oklahoma through northeast Texas, northern Louisiana and central Mississippi to an interconnect with the Transcontinental Gas Pipe Line system in Butler, Alabama. Lone Star is an entity owning a diverse set of midstream energy assets, including NGL pipelines, storage, fractionation and processing facilities located in the states of Texas, Mississippi and Louisiana.

Contract Compression Operations

The natural gas contract compression segment services include designing, sourcing, owning, installing, operating, servicing, repairing and maintaining compressors and related equipment. These field-wide applications include compression for natural gas gathering and natural gas processing. The Partnership�� contract compression operations are primarily located in Texas, Louisiana, Arkansas, Pennsylvania and California.

Contract Treating Operations

The Partnership owns and operates a fleet of equipment used to provide treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration and BTU management, to natural gas producers and midstream pipeline companies. Its contract treating operations are primarily located in Texas, Louisiana and Arkansas.

The Company competes with PELICO Pipeline, LLC (Pelico), ETP, KMP, Chesapeake Midstream Partners, L.P., Enterprise Products Partners LP, DCP Midstream Partners, L.P., Copano Energy, L.L.C, Southern Union Gas Services, Targa Resources Partners L.P., ONEOK Partners L.P., Penn Virginia Resource Partners, L.P., CenterPoint Energy Transmission, Gulf South Pipeline, L.P., Texas Gas Transmission, LLC, Gulf Crossing Pipeline, Centerpoint Energy Gas Transmission and Natural Gas Pipeline Co. of America, Ext! erran Hol! dings, Inc., Compressor Systems, Inc., USA Compression, Valerus Compression Services LP, J-W Energy Company, TransTex Gas Services, LP, Cardinal Midstream LLC, SouthTex Treaters, Interstate Treating Inc., Thomas Russell Co. and Spartan Energy Group.

Advisors' Opinion:

• [By John Kell]

  Natural gas companies Eagle Rock Energy Partners L.P(EROC). and Regency Energy Partners L.P(RGP). said the Federal Trade Commission is requesting additional information regarding Eagle Rock’s sale of its midstream business to Regency. Eagle Rock slipped 2.6% to $4.95 premarket.

• [By Igor Greenwald]

  ETE is the general partner of Energy Transfer Partners LP (ETP), the fourth-largest MLP by market value, and operator of natural gas gathering and transportation pipelines with a combined length of 47,000 miles.

  ETE is also the general partner of another pipeline operator, Regency Energy Partners (RGP).

Top 5 Heal Care Stocks To Own For 2014: First Trust Large Cap Growth AlphaDEX Fund (FTC)

First Trust Large Cap Growth AlphaDEX Fund (the Fund), formerly First Trust Large Cap Growth Opportunities AlphaDEX Fund, is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield of an equity index called the Defined Large Cap Growth Index (the Index). The Index is an enhanced index created and administered by Standard & Poor��, which employs the AlphaDEX stock selection methodology to select stocks from the S&P 500 Growth Index. Standard & Poor�� constructs the Defined Large Cap Growth Index by ranking the stocks from the S&P 500 Growth Index against all the stocks in the S&P 500 Index on growth factors including 3, 6 and 12-month price appreciation, sales to price and one year sales growth, and separately on value factors, including book value to price, cash flow to price and return on assets. First Trust Advisors L.P. is the adviser of the Fund. Advisors' Opinion:

• [By reports.droy]

  Dollar General�� management still remains optimistic as they have remarked that the ��nti-trust issues��are manageable. Company sources have confirmed that on September 2, the management has sweetened the proposal and send it to the Board of Directors of Family Dollar Stores. Under the terms of the revised proposal, Dollar General is ready to increase the bid to $80 per share in an all-cash deal. To further pacify the Family Dollar top brass, Dollar General�� management has agreed to divest nearly 1500 outlets if ordered by the Federal Trade Commission (FTC), from the 700 store divestiture commitment given during the initial bid.

Top 5 Heal Care Stocks To Own For 2014: Weir Group PLC (WEIR)

The Weir Group PLC is engaged in engineering businesses. It operates in three segments: Minerals, Oil and Gas, and Power and Industrial. The Minerals segment provides slurry handling equipment and associated aftermarket support for abrasive high wear applications used in the mining and oil sands markets. The Oil & Gas segment provides products and service solutions to upstream, production, transportation, refining and related industries. The Power & Industrial segment designs and manufactures valves, pumps and turbines as well as providing specialist support services to the global power generation, industrial and oil and gas sectors. The Company�� subsidiaries include American Hydro Corporation, EnviroTech Pumpsystems Inc, Gema Industrigummi AB, Linatex Rubber Products Sdn Bhd and Mesa Manufacturing Inc. Advisors' Opinion:

• [By Inyoung Hwang]

  Weir Group Plc (WEIR) added 1.6 percent to 2,239 pence, the highest price in almost two months. The U.K.�� largest supplier of pressure pumps was raised to buy from hold at Berenberg Bank.